COMPASS Trial Recommendation for Stable Atherosclerotic Cardiovascular Disease
The COMPASS trial recommends aspirin 100 mg once daily plus rivaroxaban 2.5 mg twice daily for long-term secondary prevention in patients with stable atherosclerotic cardiovascular disease, as this combination reduces cardiovascular death, stroke, and myocardial infarction by 24% compared to aspirin alone. 1
Core Evidence from COMPASS
The landmark COMPASS trial (n=27,395) was stopped early for superiority after demonstrating that the combination of rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily significantly reduced the primary composite outcome (cardiovascular death, stroke, or MI) compared to aspirin alone: 4.1% vs 5.4% (HR 0.76,95% CI 0.66-0.86, P<0.001). 1 Importantly, this regimen also reduced all-cause mortality (3.4% vs 4.1%, HR 0.82, P=0.01). 1
The rivaroxaban 5 mg twice daily monotherapy arm did NOT show benefit over aspirin alone and is not recommended. 1
Current Guideline Integration
The 2024 ESC Guidelines for Chronic Coronary Syndromes incorporate COMPASS findings, noting that rivaroxaban 2.5 mg twice daily plus aspirin reduced ischemic events but increased modified-ISTH major bleeding compared with aspirin alone in patients with stable atherosclerotic disease. 2 This dual anti-thrombotic pathway inhibition (DAPI) strategy targets both platelet activation (via aspirin) and coagulation (via factor Xa inhibition). 3
Bleeding Risk Trade-off
Major bleeding events occurred more frequently with the combination: 3.1% vs 1.9% (HR 1.70,95% CI 1.40-2.05, P<0.001). 1 However, there was no significant increase in intracranial or fatal bleeding—the most clinically devastating bleeding complications. 1 The net clinical benefit analysis showed 20% fewer adverse outcomes (cardiovascular death, stroke, MI, fatal bleeding, or symptomatic bleeding into critical organs) with combination therapy (HR 0.80,95% CI 0.70-0.91, P=0.0005), driven primarily by efficacy events rather than bleeding. 4
Patients Who Benefit Most
Absolute risk reduction is greatest in high-risk subgroups: 3, 4
- Polyvascular disease (≥2 vascular beds affected)
- Type 2 diabetes mellitus
- Heart failure
- Chronic kidney disease
- Peripheral artery disease
These patients derive larger absolute benefits from the combination therapy, making the bleeding risk more acceptable.
Long-term Safety Data
Extended treatment data from the COMPASS open-label extension (median 374 additional days, maximum 3 years) showed sustained efficacy with incident rates for cardiovascular death/stroke/MI of 2.35 per 100 patient-years, with major bleeding rates actually lower during extended treatment (1.01 per 100 patient-years) compared to the randomized phase (1.67 per 100 patient-years). 5 This suggests the bleeding risk may attenuate over time while efficacy persists.
Critical Implementation Points
Avoid these common pitfalls:
- Do NOT use rivaroxaban 5 mg twice daily monotherapy—it showed no benefit over aspirin and increased bleeding 1
- Do NOT use this combination in patients with high bleeding risk (active bleeding, recent major bleeding, severe renal impairment)
- The specific dose of rivaroxaban 2.5 mg twice daily is critical—this is a vascular dose, not an anticoagulation dose
- Aspirin dose should be 100 mg once daily (75-100 mg acceptable range)
Practical Algorithm
For patients with stable CAD or PAD:
- High ischemic risk (polyvascular disease, diabetes, heart failure, CKD) + acceptable bleeding risk → Rivaroxaban 2.5 mg BID + aspirin 100 mg daily
- Standard risk or high bleeding risk → Aspirin monotherapy (or clopidogrel as alternative per 2024 ESC guidelines) 2
- Reassess bleeding risk at 3-6 months; if major bleeding occurs, revert to antiplatelet monotherapy
The 2024 ESC guidelines position aspirin or clopidogrel monotherapy as the general recommendation for long-term secondary prevention in CCS patients without indication for oral anticoagulation, with the COMPASS regimen representing an intensified strategy for selected high-risk patients. 2